NCT07164885 RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
| NCT ID | NCT07164885 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Capital Medical University |
| Condition | Locally Advanced Non-small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 911 participants |
| Start Date | 2025-02-17 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 911 participants in total. It began in 2025-02-17 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.
Eligibility Criteria
Inclusion Criteria: * Adult research participants, aged over 18 years old; * Non small cell lung cancer that requires pathological confirmation; * All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3); * ECOG physical condition is 0-2; * In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment. Exclusion Criteria: * Prisoners who are not convenient for close clinical follow-up; * Study participants with contraindications to radiation therapy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07164885 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07164885 currently recruiting?
Yes, NCT07164885 is actively recruiting participants. Contact the research team at kong0001@hku.hk for enrollment information.
Where is the NCT07164885 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07164885 clinical trial?
NCT07164885 is sponsored by Capital Medical University. The trial plans to enroll 911 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.